Patents, a traditional financial engine for biotech, are harder to win for plants that have been around for centuries, or molecules that have already made the rounds as street drugs. The next legal battlefront of drug development is the patents on psychedelics - will the rush to protect formulations simply to block competition hinder patenting an innovation that’s useful to patients? Will patents affect the barriers to entry for scientific research? The cost of accessing these therapies?
Other Resources / Information
- Ethics: who should profit & what should they control Possibility of issuing bad patents - the rush to block competition vs. patenting innovation
- Creating a niche patent that benefits the industry - filing patents that are chemically new vs. formulations of existing drugs and natural products
- Synthetic vs. natural psychedelics - developing drugs with efficacy and precision in mind
- Joseph Araujo, Chief Scientific Officer, Mindset Pharma
- Jim Gilligan, President and Chief Scientific Officer, Tryp Therapeutics
- Olivia Goodhill, Investigative Reporter, Health and Science, Stat News
- Amy Emerson, Chief Executive Officer, MAPS Public Benefit Corporation
Sirita Wright, Senior Account Executive, KCSA Strategic Communications
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.